Challenges in the prevention, diagnosis, and treatment of malaria in human immunodeficiency virus-infected adults in sub-Saharan Africa

Archives of Internal Medicine

Volumn 167, Issue 17, 2007, Pages 1827-1836

  Brentlinger, Paula E ^a,b   Behrens, Christopher B ^b,c   Kublin, James G ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMODIAQUINE; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ARTEMISININ; ARTESUNATE; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; COTRIMOXAZOLE; EFAVIRENZ; FANSIDAR; HALOFANTRINE; INDINAVIR; ISONIAZID; LAMIVUDINE; MEFLOQUINE; NEVIRAPINE; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUININE; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; ZIDOVUDINE;

ABNORMAL DREAMING; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; AGRANULOCYTOSIS; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD DYSCRASIA; BLOOD TOXICITY; CARDIOTOXICITY; CD4 LYMPHOCYTE COUNT; CLINICAL EXAMINATION; CLINICAL FEATURE; CONSTIPATION; DEPRESSION; DIAGNOSTIC ACCURACY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; EOSINOPHILIA; FEVER; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; INCIDENCE; INSOMNIA; LABORATORY DIAGNOSIS; LACTIC ACIDOSIS; LIVER TOXICITY; MALARIA; MEDLINE; MENTAL CONCENTRATION; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OPPORTUNISTIC INFECTION; PLASMODIUM FALCIPARUM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; RETICULOCYTE COUNT; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; SUPERINFECTION; THROMBOCYTOPENIA; VIRUS LOAD; VOMITING; WEAKNESS; WORLD HEALTH ORGANIZATION;

AFRICA SOUTH OF THE SAHARA; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; MALARIA, FALCIPARUM; PRACTICE GUIDELINES; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 34748825499     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.17.1827     Document Type: Review

References (119)

1. World Health Organization. World Malaria Report, 2005. Geneva, Switzerland: World Health Organization; 2006.
2. Joint United Nations Programme on HIV/AIDS (UNAIDS). Report on the Global AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2006.
3. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science. 2006;314(5805):1603-1606.
4. Brentlinger PE, Behrens CB, Micek MA. Challenges in the management of malaria and HIV in pregnancy in sub-Saharan Africa. Lancet Infect Dis. 2006;6(2):100-111.
5. Qazi SA, Muhe L. Integrating HIV management for children into the Integrated Management of Childhood Illness guidelines. Trans R Soc Trop Med Hyg. 2006;100(1):10-13.
6. De Baets AJ, Bulterys M, Abrams EJ, Kankassa C, Pazvakavambwa IE. Care and treatment of HIV-infected children in Africa: issues and challenges at the district hospital level. Pediatr Infect Dis J. 2007;26(2):163-173.
7. World Health Organization. WHO Case Definitions of HIV for Surveillance and Revised Clinical Staging and Immunological Classification of HIV-related Disease in Adults and Children. Geneva, Switzerland: World Health Organization; 2006.
8. World Health Organization. Integrated Management of Adolescent and Adult Illness: Acute Care: Interim Guidelines for First-Level Facility Health Workers at Health Centre and District Outpatient Clinic. Geneva, Switzerland: World Health Organization; October 2005.
9. Médecins Sans Frontières. Clinical HIV/AIDS Care Guidelines for Resource-Poor Settings. Brussels, Belgium: Médecins Sans Frontières Operations Centre; April 2006.
10. International Center for AIDS Care and Treatment Programs, Columbia University Mailman School of Public Health. The Columbia Clinical Manual. New York, NY: Columbia University; September 2004.
11. World Health Organization. Guidelines for the Treatment of Malaria. Geneva, Switzerland: World Health Organization; 2006.
12. Severe falciparum malaria: World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000;94(suppl 1):S1-S90.
13. World Health Organization. Integrated Management of Adolescent and Adult Illness: Chronic HIV Care With ARV Therapy: Interim Guidelines for First-Level Facility Health Workers. Geneva, Switzerland: World Health Organization; 2004.
14. World Health Organization. Technical Consultation on Malaria and HIV Interactions and Public Health Policy Implications. Geneva, Switzerland: World Health Organization; 2004.
15. World Health Organization. Guidelines on Cotrimoxazole Prophylaxis for HIV-Related Infections Among Children, Adolescents and Adults in Resource-Limited Settings: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2006.
16. Grimwade K, French N, Mbatha DD, Zungu D, Dedicoat M, Gilks CF. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS. 2004;18(3):547-554.
17. Cohen C, Karstaedt A, Frean J, et al. Increased prevalence of severe malaria in HIV-1-infected adults in South Africa. Clin Infect Dis. 2005;41(11):1631-1637.
18. Shah SN, Smith E, Obonyo C, et al. HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. J Infect Dis. 2006;194(11):1519-1528.
19. Van Geertruyden J-P, Mulenga M, Mwananyanda L, et al. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis. 2006;194(7):917-925.
20. Colebunders R, Bahwe Y, Nekwei W, et al. Incidence of malaria and efficacy of oral quinine in patients recently infected with human immunodeficiency virus in Kinshasa, Zaire. J Infect. 1990;21(2):167-173.
21. Müller O, Moser R. The clinical and parasitological presentation of Plasmodium falciparum malaria in Uganda is unaffected by HIV-1 infection. Trans R Soc Trop Med Hyg. 1990;84(3):336-338.
22. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in blood of adults in rural Malawi: a prospective cohort study. Lancet. 2005;365(9455):233-240.
23. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stages of HIV-1 infection, Rakai, Uganda. J Infect Dis. 2005;191(9):1403-1409.
24. Cohen MS, Pilcher C. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis. 2005;191(9):1391-1393.
25. Palacios R, Jiménez-Oñate F, Aguilar M, et al. Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. J Acquir Immune Defic Syndr. 2007;44(3):356-359.
26. Mermin J, Lule JR, Ekwaru JP. Association between malaria and CD4 cell count decline among persons with HIV. J Acquir Immune Defic Syndr. 2006;41(1):129-130.
27. Sara E, Kotsakis A, Souklakos J, et al. Postchemotherapy lymphopoiesis in patients with solid tumors is characterized by CD4+ proliferation. Anticancer Res. 1999;19(1A):471-476.
28. Hughes MA, Parisi M, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys. 2005;62(5):1423-1426.
29. Singhal M, Banavalikar J, Sharma S, Saha K. Peripheral blood T lymphocyte subpopulations in patients with tuberculosis and the effect of chemotherapy. Tubercle. 1989;70(3):171-178.
30. Anglaret X, Dakoury-Dogbo N, Bonard D, et al. Causes and empirical treatment of fever in HIVinfected adult outpatients, Abidjan, Côte d'Ivoire. AIDS. 2002;16(6):909-918.
31. Lawn SD, Bekker L-G, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis. 2005;5(6):361-373.
32. Sande M, Eliopoulos G, Moellering R, Gilbert D. The Sanford Guide to HIV/AIDS Therapy 2006-7. 15th ed. Sperryville, VA: Antimicrobial Therapy, Inc; 2006.
33. Lewis DK, Whitty CJM, Walsh AL, et al. Treatable factors associated with severe anaemia in adults admitted to medical wards in Blantyre, Malawi, an area of high HIV seroprevalence. Trans R Soc Trop Med Hyg. 2005;99(8):561-567.
34. Katz KC, Walmsley SL, McLeod AG, Keystone JS, Detsky AS. Clinical problem-solving: where are you from? N Engl J Med. 2002;346(10):764-767.
35. Moore RD, Fortgang I, Keruly J, Chaisson RE. Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med. 1996;101(1):34-40.
36. Moh R, Danel C, Sorho S, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther. 2005;10(5):615-624.
37. Daley CL. Pulmonary infection in the tropics: impact of HIV infection. Thorax. 1994;49(4):370-378.
38. Laufer MK, van Oosterhout JJ, Thesing PC, et al. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis. 2006;193(6):872-878.
39. Calza L, Manfredi R, Chiodo F. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy. Clin Nutr. 2005;24(1):5-15.
40. Geddes R, Knight S, Moosa MY, Reddi A, Uebel K, Sunpath H. A high incidence of nucleoside reverse transcriptor inhibitor (NRTI)-induced acidosis in HIV-infected patients in a South African context. S Afr Med J. 2006;96(8):722-724.
41. Monkemuller KE, Wilcox CM. Diseases of the esophagus, stomach, and bowel. In: Dolin R, Masur H, Saag MS, eds. AIDS Therapy. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2003:885-901.
42. Chung RT, Sherman KE. Hepatic and hepatobiliary diseases. In: Dolin R, Masur H, Saag MS, eds. AIDS Therapy. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2003:902-920.
43. Walker M, Kublin JG, Zunt J. Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis. Clin Infect Dis. 2006;42(1):115-125.
44. Price RW. Neurologic disease. In: Dolin R, Masur H, Saag MS, eds. AIDS Therapy. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2003: 737-757.
45. Hoffman IF, Jere CS, Taylor TE, et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS. 1999;13(4):487-494.
46. Pichyangkul S, Yongvanitchit K, Kum-arb U, et al. Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a toll-like receptor 9 - dependent pathway. J Immunol. 2004;172(8):4926-4933.
47. Pisell TL, Hoffman IF, Jere CS, et al. Immune activation and induction of HIV-1 replication within CD14 macrophages during acute Plasmodium falciparum malaria coinfection. AIDS. 2002;16(11):1503-1509.
48. Clerici M, Butto S, Lukwiya M, et al; Italian-Ugandan AIDS Project. Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. AIDS. 2000;14(14):2083-2092.
49. Xiao L, Owen SM, Rudolph DL, Lal RB, Lal AA. Plasmodium falciparum antigen-induced human immunodeficiency virus type 1 replication is mediated through induction of tumor necrosis factor-alpha. J Infect Dis. 1998;177(2):437-445.
50. Froebel K, Howard W, Schaefer JR, et al. Activation by malaria antigens renders mononuclear cells susceptible to HIV infection and reactivates replication of endogenous HIV in cells from HIV-infected adults. Parasite Immunol. 2004;26(5):213-217.
51. Van Geertruyden J-P, Mulenga M, Kasongo W, et al. CD4 T-cell count and HIV-1 infection in adults with uncomplicated malaria. J Acquir Immune Defic Syndr. 2006;43(3):363-367.
52. Kassa D, Petros B, Mesele T, Hailu E, Wolday D. Characterization of peripheral blood lymphocyte subsets in patients with acute Plasmodium falciparum and P. vivax malaria infections at Wonji sugar estate, Ethiopia. Clin Vaccine Immunol. 2006;13(3):376-379.
53. Chandramohan D, Greenwood BM. Is there an interaction between human immunodeficiency virus and Plasmodium falciparum? Int J Epidemiol. 1998;27(2):296-301.
54. French N, Gilks CF. Royal Society of Tropical Medicine and Hygiene Meeting at Manson House, London, 18 March 1999: fresh from the field: some controversies in tropical medicine and hygiene: HIV and malaria, do they interact? Trans R Soc Trop Med Hyg. 2000;94(3):233-237.
55. French N, Nakiyingi J, Lugada E, Watera C, Whitworth JA, Gilks CF. Increasing rates of malarial fever with deteriorating immune status in HIV-1 - infected Ugandan adults. AIDS. 2001;15(7):899-906.
56. Whitworth J, Morgan D, Quiqley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet. 2000;356(9235):1051-1056.
57. Chirenda J, Siziya S, Tshimanga M. Association of HIV infection with the development of severe and complicated malaria cases at a rural hospital in Zimbabwe. Cent Afr J Med. 2000;46(1):5-9.
58. Holmes CB, Losina E, Walensky RP, Yazdanpanah Y, Freedberg K. Review of human immunodeficiency virus type 1 - related opportunistic infections in sub-Saharan Africa. Clin Infect Dis. 2003;36(5):652-662.
59. Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resourcepoor settings: the case of Côte d'Ivoire. N Engl J Med. 2006;355(11):1141-1153.
60. Korenromp EL, Williams B, de Vlas S, et al. Malaria attributable to the HIV-1 epidemic, sub-Saharan Africa. Emerg Infect Dis. 2005;11(9):1410-1419.
61. Ryan C, Madalon M, Wortham DW, Graziano FM. Sulfa hypersensitivity in patients with HIV infection: onset, treatment, critical review of the literature. WMJ. 1998;97(5):23-27.
62. Tréluyer JM, Roux A, Mugnier C, Flouvat B, Lagardere B. Metabolism of quinine in children with global malnutrition. Pediatr Res. 1996;40(4):558-563.
63. Salako LA, Sowunmi A, Akinbami FO. Pharmacokinetics of quinine in African children suffering from kwashiorkor. Br J Clin Pharmacol. 1989;28(2):197-201.
64. Giao PT, de Vries P. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet. 2001;40(5):343-373.
65. Hughes WT, LaFon S, Scott JD, Masur H. Adverse events associated with trimethoprimsulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J Infect Dis. 1995;171(5):1295-1301.
66. Gimnig JE, MacArthur JR, M'bang'ombe M, et al. Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg. 2006;74(5):738-743.
67. Tagbor H, Bruce J, Browne E, Randal A, Greenwood B, Chandramohan D. Efficacy, safety, and tolerability of amodiaquiine plus sulphadoxine- pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trial. Lancet. 2006;368(9544):1349-1356.
68. White NJ. Malaria. In: Cook GC, Zumla A, eds. Manson's Tropical Diseases. 21th ed. Philadelphia, PA: WB Saunders; 2003:1205-1295.
69. Olliaro P, Mussano P. Amodiaquine for treating malaria. Cochrane Database Syst Rev. 2003;(2):CD000016. doi:10.1002/14651858.CD000016.
70. Taylor WRJ, White NJ. Antimalarial drug toxicity. Drug Saf. 2004;27(1):25-61.
71. German P, Greenhouse B, Coates C, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007;44(6):889-891.
72. Toure S, Gabillard D, Inwoley A, Seyler C, Gourvellec G, Anglaret X. Incidence of neutropenia in HIV-infected African adults receiving cotrimoxazole prophylaxis: a 6-year cohort study in Abidjan, Côte d'Ivoire. Trans R Soc Trop Med Hyg. 2006;100(8):785-790.
73. Myint HY, Tipmanee P, Nosten F, et al. A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg. 2004;98(2):73-81.
74. Ward SA, Sevene EP, Hastings IM, Nosten F, McGready R. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis. 2007;7(2):136-144.
75. Talisuna AO, Staedke SG, D'Alessandro U. Pharmacovigilance of antimalarial treatment in Africa: is it possible? Malar J. 2006;5:50. doi:10.1186/1475-2875-5-50.
76. Parikh S, Ouedraogo J-B, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007;82(2):197-203.
77. Liverpool HIV Pharmacology Group. Home page. http://www.hiv- druginteractions.org. Accessed November 29, 2006. 78. Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS. 2005;19(10):995-1005.
78. World Health Organization. Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria. Geneva, Switzerland: World Health Organization; 2003.
79. Mishra LC, Bhattacharya A, Bhasin VK. Antiplasmodial interactions between artemisinin and triclosan or ketoconazole combinations against blood stages of Plasmodium falciparum in vitro. Am J Trop Med Hyg. 2007;76(3):497-501.
80. Bindschedler M, Lefevre G, Degen P, Sioufi A. Comparison of the cardiac effects of the antimalarials coartemether and halofantrine in healthy participants. Am J Trop Med Hyg. 2002;66(3):293-298.
81. Lefèvre G, Carpenter P, Souppart C, Schmidli H, McClean M, Stypinski D. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet®) with concomitant administration of ketoconazole in healthy subjects. Br J Clin Pharmacol. 2002;54(5):485-492.
82. Karp C. Prophylaxis and treatment of malaria in the presence of HIV protease inhibitor therapy. http://www.hopkins-aids.edu/karpsum/pi.html. Accessed July 4, 2007.
83. Pukrittayakamee S, Prakongpan S, Wanwimolruk S, Clemens R, Looareesuwan S, White NJ. Adverse effect of rifampin on quinine efficacy in uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2003;47(5):1509-1513.
84. Iyer JK, Milhous W, Cortese J, Kublin J, Plowe C. Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet. 2001;358(9287):1066-1067.
85. Girosi F, Olmsted SS, Keeler E, et al. Developing and interpreting models to improve diagnostics in developing countries. Nature. 2006;444(suppl 1):3-8. doi:10.1038/nature05441.
86. Watkins WM, Sibley CH, Hastings IM. The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations. Am J Trop Med Hyg. 2005;72(2):163-173.
87. Shretta R, Omumbo J, Rapuoda B, Snow RW. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health. 2000;5(11):755-764.
88. Anglaret X, Chene G, Attia A, et al; Cotrimo-CI Study Group. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet. 1999;353(9163):1463-1468.
89. Mermin J, Lule J, Ekwaru J, et al. Effect of cotrimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV-infection in rural Uganda. Lancet. 2004;364(9443):1428-1434.
90. Rosenthal PJ. Proteases of malaria parasites: new targets for chemotherapy. Emerg Infect Dis. 1998;4(1):49-57.
91. Nathoo S, Serghides L, Kain K. Effect of HIV-1 antiretroviral drugs on cytoadherence and phagocytic clearance of Plasmodium falciparum-parasitised erythrocytes. Lancet. 2003;362(9389):1039-1041.
92. Skinner-Adams TS, McCarthy J, Gardiner D, Hilton P, Andrews K. Antiretrovirals as antimalarial agents. J Infect Dis. 2004;190(11):1998-2000.
93. Andrews KT, Fairlie DP, Madala PK, et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother. 2006;50(2):639-648.
94. Skinner-Adams TS, Andrews KT, Melville L, McCarthy J, Gardiner DL. Synergistic interactions of the antiretroviral protease inhibitors saquinavir and ritonavir with chloroquine and mefloquine against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 2007;51(2):759-762.
95. Parikh S, Gut J, Istvan E, Goldberg DE, Havlir DV, Rosenthal PJ. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother. 2005;49(7):2983-2985.
96. Peters RPH, Zijlstra EE, Schijffelen MJ, et al. A prospective study of bloodstream infections as a cause of fever in Malawi: clinical predictors and implications for management. Trop Med Int Health. 2004;9(8):928-934.
97. Archibald LK, McDonald LC, Nwanyanwu O, et al. A hospital-based prevalence survey of bloodstream infections in febrile patients in Malawi: implications for diagnosis and therapy. J Infect Dis. 2000;181(4):1414-1420.
98. Zurovac D, Larson BA, Akhwale W, Snow RW. The financial and clinical limitations of adult malaria diagnosis using microscopy in Kenya. Trop Med Int Health. 2006;11(8):1185-1194.
99. Nwanyanwu OC, Kumwenda N, Kazembe PN, et al. Malaria and human immunodeficiency virus infection among male employees of a sugar estate in Malawi. Trans R Soc Trop Med Hyg. 1997;91(5):567-569.
100. Casals-Pascual C, Kai O, Cheung JOP, et al. Suppression of erythropoiesis in malarial anemia is associated with hemozoin in vitro and in vivo. Blood. 2006;108(8):2569-2577.
101. Menendez C, Fleming AF, Alonso P. Malaria-related anaemia. Parasitol Today. 2000;16(11):469-476.
102. Belperio PS, Rhew DC. Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004;116(7A):27S-43S.
103. Moore RD, Creagh-Kirk T, Keruly J, et al; Zidovudine Epidemiology Study Group. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Arch Intern Med. 1991;151(5):981-986.
104. Haas JD, Brownlie T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr. 2001;131(2S-2):676S-690S.
105. Brabin BJ, Hakimi M, Pelletier D. An analysis of anemia and pregnancy-related maternal mortality. J Nutr. 2001;131(2)(suppl 2):604S-615S.
106. Stringer JSA, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia. JAMA. 2006;296(7):782-793.
107. Olsen A, Magnussen P, Ouma JH, Andreassen J, Friis H. The contribution of hookworm and other parasitic infections to hemoglobin and iron status among children and adults in western Kenya. Trans R Soc Trop Med Hyg. 1998;92(6):643-649.
108. World Health Organization. HIV/AIDS Programme. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. Rev ed. Geneva, Switzerland: World Health Organization; 2006.
109. Sharma OP, Maheshwari A. Lung diseases in the tropics, part 2: common tropical lung diseases: diagnosis and management. Tuber Lung Dis. 1993;74(6):359-370.
110. Maguire GP, Handojo T, Pain MCF, et al. Lung injury in uncomplicated and severe falciparum malaria: a longitudinal study in Papua, Indonesia. J Infect Dis. 2005;192(11):1966-1974.
111. Källander K, Nsungwa-Sabiiti J, Peterson S. Symptom overlap for malaria and pneumonia: policy implications for home management strategies. Acta Trop. 2004;90(2):211-214.
112. Dondorp A, Nosten F, Stepniewska K, Day N, White N; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) Group. Artesunate versus quinine for treatment of severe malaria: a randomised trial. Lancet. 2005;366(9487):717-725.
113. Rénia L, Potter S. Co-infection of malaria with HIV: an immunological perspective. Parasite Immunol. 2006;28(11):589-595.
114. Stephens R, Langhorne J. Priming of CD4+ T cells and development of CD4+ T cell memory; lessons for malaria. Parasite Immunol. 2006;28(1-2):25-30.
115. Leaver RJ, Haile Z, Watters DA. HIV and cerebral malaria. Trans R Soc Trop Med Hyg. 1990;84(2):201.
116. Simooya OO, Mwendapole R, Sikateyo B. Severe falciparum malaria and the acquired immunodeficiency syndrome (AIDS) in Zambia. Ann Trop Med Parasitol. 1991;85(2):269-270.
117. Clark IA, Budd A, Alleva L, Cowden W. Human malarial disease: a consequence of inflammatory cytokine release. Malar J. 2006;5:85. doi:10.1186/1475-2875-5-85.
118. Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1 - infected adults in Uganda: a prospective cohort study. Lancet. 2006;367(9518):1256-1261.
119. Baillargeon J, Borucki MJ, Williamson J. Temporal trends in AIDS-related survival. AIDS Patient Care STDS. 1999;13(1):17-22.